Data & Sample Collection for Frail or Relapsed Large B-cell Lymphoma
Part of Cancer clinical trials.
This study collects information and samples from people with large B-cell lymphoma who are either too frail for standard chemo, or whose disease has come back after one prior treatment. The goal is to better understand how to treat these situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have a type of large B-cell lymphoma that has been confirmed by a biopsy.
- You may be either newly diagnosed and frail (unable to handle full-dose chemo), OR your lymphoma has come back or not responded after one prior treatment (including CAR-T).
- You have not had lymphoma in your brain or spinal cord.
- If you had treatment before, it must have started less than 6 months ago and you are still being followed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
This study collects and analyzes tumor samples from people diagnosed with a type of brain lymphoma to learn more about the disease and improve future treatments.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.